Bolder BioPath

About Us
Services
Publications
Request a Quote
Contact

Contact

Bolder BioPATH

Phone: 303-633-5400
info@bolderbiopath.com

Name*
Company
Phone
Email*
Question or Comment*
CAPTCHA

Tell Us About Your Project! Get a Quote »

Contact Us

CAPTCHA
Phone
This field is for validation purposes and should be left unchanged.

Recent Posts

A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

05-02-17

Come hear Leo Fitzpatrick discuss the paper, A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice, this Saturday May 6, from 10:30am-10:45am in Room S102d at McCormick Place, California NorthState University College of Pharmacy. Authors: Leo Fitzpatrick, Robert O’Connell, George Talbott, Phillip Bendele, Gordon Alton, Jim Zapf

AAALAC Accreditation

03-14-17

Bolder BioPATH now has FULL accreditation through AAALAC International, effective as of March 9, 2017.
OARSI 2017 World Congress on Osteoarthritis

01-24-17

Come meet Bolder BioPATH at the OARSI 2017 World Congress on Osteoarthritis in Las Vegas from April 27 to 30! We’ll be set up in booth #8.

Digestive Disease Week Conference, May 6-9

12-22-16

Come meet Bolder BioPATH at the DDW Conference in Chicago from May 6 to 9! We’ll be set up in booth #1712.
Important Things to Know About Intra-Articular Testing of Drugs in Animals – ACT’s 37th Annual Meeting

08-25-16

Important Things to Know About Intra-Articular Testing of Drugs in Animals Alison M. Bendele DVM, PhD, DACVP Bolder BioPATH, Inc, Boulder, CO Monday Nov. 7th – Symposium 7 , 3:50 PM–4.20 PM Intra-articular (IA) administration of drugs offers an opportunity to directly target joints (primarily osteoarthritic) for anabolic, antidegenerative, analgesic, lubricant, anti-inflammatory and other potential […]

Now offering FACS analysis through Clinimmune Labs.

08-23-16

Bolder BioPATH has started offering FACS analysis on some of our models with help from the folks at Clinimmune Labs in Denver.
19th IRA International Conference – 2016

07-22-16

Come by Bolder BioPATH’s booth at the 19th IRA International Conference in San Diego. We hope to see you there!

Atlas-Backed Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership

04-26-16

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here).

Website designed by Studio98

In Vivo efficacy models
Ex Vivo Services
Pathology
Terms of Service
Privacy Policy

©2015 Bolder BioPATH, INC. All rights reserved.Privacy Policy